Ginkgo Bioworks Holdings Inc (NYSE:DNA) Fits the Minervini Trend Template with Strong Technicals and High-Growth Momentum

Ginkgo Bioworks Holdings Inc (NYSE:DNA) has become a possible choice for investors using the Mark Minervini Trend Template and high-growth momentum strategies. The Minervini method blends strict technical screening with fundamental growth measures to find stocks showing strong upward trends and increasing earnings potential. This approach highlights stocks in Stage 2 uptrends, confirmed by moving averages, relative strength, and price action, while also needing solid earnings growth, revenue growth, and better margins to support fundamental momentum.

Why DNA Fits the Minervini Trend Template

The Trend Template looks for stocks with steady upward momentum, and DNA meets several important criteria:

• Price Above Key Moving Averages: DNA’s current price ($13.14) is above its 50-day ($9.83), 150-day ($9.40), and 200-day ($9.19) moving averages, all of which are moving higher. This confirms both short-term and long-term positive trends.
• Relative Strength: With a ChartMill Relative Strength (CRS) score of 91.19, DNA performs better than 91% of stocks in its sector (Chemicals), a sign of market leadership.
• Distance from 52-Week High/Low: The stock is trading within 25% of its 52-week high ($16.85) and well above its 52-week low ($5.00), suggesting potential for further recovery.

These technical factors match Minervini’s requirements for stocks in Stage 2 accumulation, where institutional buying often leads to more gains.

High Growth Momentum Fundamentals

Beyond technicals, DNA shows improving growth metrics that attract momentum investors:

• Earnings Growth:

  • Quarterly EPS growth (Q2Q) is 47.5%, with earlier quarters showing even better results (54.55% in Q-1, 85.31% in Q-2).
  • Full-year EPS growth (TTM) is 57.84%, showing steady profit growth.
  • The company has exceeded EPS estimates in 3 of the last 4 quarters, with an average surprise of 17.79%.

• Revenue Growth:

  • Quarterly revenue growth (Q2Q) is 27.34%, with earlier quarters showing notable increases (26.16% in Q-1, 60.73% in Q-2).
  • Revenue beats have happened in 3 of the last 4 quarters, averaging 36.55% above estimates.

• Upward Revisions:

  • Analysts have increased next-year EPS estimates by 0.05% and revenue forecasts by 2.99% over the past three months, showing confidence.

These fundamentals indicate DNA is not only technically strong but also well-positioned for continued growth—a key part of Minervini’s SEPA (Specific Entry Point Analysis) method.

Technical Summary

ChartMill’s technical report gives DNA a rating of 9/10, noting:

• A positive long- and short-term trend.
• Strong relative strength compared to peers.
• Support levels between $12.87–$13.13 and $10.34–$10.39, offering downside protection.
• Resistance near $14.73–$14.91, which, if surpassed, could lead to more gains.

While the setup quality is currently rated 5/10 due to recent volatility, the stock’s technical condition remains solid. For more details, see the full technical analysis here.

Next Steps for Investors

DNA’s mix of technical strength and high-growth fundamentals makes it an interesting watchlist option for Minervini-style investors. Those looking for similar opportunities can find more high-growth momentum stocks using our predefined screen here.

Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Always conduct your own research or consult a financial advisor before making investment decisions.